Publications by authors named "O Vornicova"
Background: Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood.
View Article and Find Full Text PDFArticle Synopsis
- The phase 1b METSSAR trial evaluated a split-dose schedule of selinexor for advanced soft tissue sarcoma patients, aiming to reduce toxicity while maintaining efficacy.
- The new dosing regimen showed no grade ≥ 3 treatment-related adverse events (TRAEs), and only mild toxicities like nausea and fatigue were reported, with some patients needing dose reductions.
- Patients experienced a median progression-free survival of 4 months, indicating that the new schedule was tolerable and potentially more beneficial than the standard dosing.
Unlike the intense research effort devoted to exploring the significance of heparanase in cancer, very little attention was given to Hpa2, a close homolog of heparanase. Here, we explored the role of Hpa2 in breast cancer. Unexpectedly, we found that patients endowed with high levels of Hpa2 exhibited a higher incidence of tumor metastasis and survived less than patients with low levels of Hpa2.
View Article and Find Full Text PDFBackground: Immune-checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAEs) in a significant proportion of patients. The mechanisms underlying irAEs development are mostly unknown and might involve multiple immune effectors, such as T cells, B cells and autoantibodies (AutoAb).
Methods: We used custom autoantigen (AutoAg) microarrays to profile AutoAb related to irAEs in patients receiving ICI.
Recent advances in treating cutaneous melanoma have resulted in impressive patient survival gains. Refinement of disease staging and accurate patient risk classification have significantly improved our prognostic knowledge and ability to accurately stratify treatment. Undoubtedly, the most important step towards optimizing patient outcomes has been the advent of cancer immunotherapy, in the form of immune checkpoint inhibition (ICI).
View Article and Find Full Text PDF